T1DM is an autoimmune disorder characterized by the destruction of beta cells, resulting in an absolute deficiency of insulin ...

MyndMed™’s formula, developed by BioAdaptives’ research team, incorporates a precise blend of botanical extracts, amino acids, and neuro-support nutrients designed to support neurotransmitter balance, ...

Inspire is scheduled to present at 11:00 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos ® (Zongertinib). The Food and Drug Administration approved ...

King Faisal Specialist Hospital and Research Centre (KFSHRC) delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth highlights how telehealth has become ...

Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery (BIOS), today announced the close of a $42 million Series C ...

Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York Links for live webcasts and replays, if available, will be available in the on the “Investors” ...

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, ...

Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that ...

CHARLOTTE, N.C., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Hemp Hop, a trusted name in premium hemp products since 2018, has just ...

With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial ...

Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 ...